PIVYA

Growth

pivmecillinam

NDAORALTABLETPriority Review

Approved

Apr 2024

Lifecycle

Growth

Competitive Pressure

30/100

Mechanism of Action

[see Microbiology ( )] .

Indications (5)

female patients 18 years of age older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli Proteus mirabilis Staphylococcus saprophyticus older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli (E

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers